Industry News

Biotechnology Industry News

Following Merck and Moderna’s…

August 28th, 2026|FierceBiotech|

Following Merck and Moderna’s phase 3 triumph with a Keytruda-paired personalized mRNA cancer vaccine, a similar shot from BioNTech and Genentech has faltered in a reminder of the approach’s struggles as a standalone therapy.

AusperBio Therapeutics has raised…

August 28th, 2026|FierceBiotech|

AusperBio Therapeutics has raised $120 million in series C funds to advance its oligonucleotide therapy for chronic hepatitis B through phase 3 testing and hopefully on to commercialization.

Roche has decided to pay $190…

August 28th, 2026|FierceBiotech|

Roche has decided to pay $190 million upfront for an unusual obesity mechanism after viewing preclinical data that “clearly suggests” the modality can reduce weight while preserving lean muscle, Fierce has learned.

Roche’s Genentech is paying…

August 28th, 2026|FierceBiotech|

Roche’s Genentech is paying DualityBio $45 million upfront for rights to antibody-drug conjugates (ADCs) designed for the growing pool of patients who progress after treatment with the modality. The deal is worth more than $1

September 2025 marked a low point…

August 27th, 2026|FierceBiotech|

September 2025 marked a low point for relations between the U.K. government and Big Pharma. Fierce reached out to the companies involved to see if they've softened their stance.

Osivax has licensed an influenza…

August 27th, 2026|FierceBiotech|

Osivax has licensed an influenza vaccine from GC Biopharma, positioning the biotech to build on early evidence that its midphase candidate complements traditional flu shots.

Flagship Pioneering’s ProFound…

August 26th, 2026|FierceBiotech|

Flagship Pioneering’s ProFound Therapeutics is keeping its string of high-profile partnerships going, forging a new pact with the Gates Foundation worth up to $35 million to find new drug targets for a dangerous pregnancy complication.

Just two months after Someit…

August 26th, 2026|FierceBiotech|

Just two months after Someit Sidhu, M.D., succeeded in pairing off his second special purpose acquisition company (SPAC) with Talawar Therapeutics, the biotech entrepreneur is back at it again.

Hansoh Pharmaceutical has given a…

August 26th, 2026|FierceBiotech|

Hansoh Pharmaceutical has given a bullish assessment of China’s innovative pharma sector, arguing that the industry is “fully transitioning from the ‘follower’ to the ‘frontrunner’ phase.”

Phase 2 data on Spyre…

August 26th, 2026|FierceBiotech|

Phase 2 data on Spyre Therapeutics’ anti-TL1A antibody SPY072 in rheumatoid arthritis have fallen short of expectations, prompting the biotech to deprioritize monotherapy development in the indication.

SK Biopharmaceuticals has…

August 26th, 2026|FierceBiotech|

SK Biopharmaceuticals has strengthened its epilepsy offering by paying $350 million upfront to help speed Biohaven’s Kv7 ion channel activator on its way to market.

After announcing the “tough but…

August 25th, 2026|FierceBiotech|

After announcing the “tough but necessary” decision to lay off some employees last year, Frontier Medicines is looking to the future by advancing more cancer drugs into the clinic while continuing to find partners to

Having set Metsera on its journey…

August 25th, 2026|FierceBiotech|

Having set Metsera on its journey to a $10 billion takeover, Arch Venture Partners and Population Health Partners have powered their new startup—Sentivera—to a licensing deal worth up to $1.5 billion.

The FDA has extended its review of…

August 25th, 2026|FierceBiotech|

The FDA has extended its review of Capricor Therapeutics’ Duchenne muscular dystrophy drug candidate, deferring the decision to review information the biotech submitted after a negative advisory committee vote.

TME Pharma’s hunt for a partner…

August 24th, 2026|FierceBiotech|

TME Pharma’s hunt for a partner for its brain cancer drug is closer to bearing fruit as the German biotech clings onto its hope of generating $1 billion in peak sales from the asset.

Spruce Biosciences has taken…

August 24th, 2026|FierceBiotech|

Spruce Biosciences has taken another step toward filing for FDA approval of its ultra-rare disease drug candidate, ticking off some of the manufacturing tasks needed to submit the long-awaited application.